Colleen Sjogren
Patrimonio netto: 559 440 $ in data 31/08/2026
Patrimonio netto: 559 440 $ in data 31/08/2026
Ms. Colleen Sjogren is a Chief Commercial Officer at Nuvation Bio, Inc. Ms. Sjogren was previously employed as a Senior Vice President-Sales by Madrigal Pharmaceuticals, Inc., a VP-US Sales, Sales Training & Meeting Planning by Mirati Therapeutics, Inc., and a Vice President-National Cell Therapy & Sales by Kite Pharma, Inc. She received her undergraduate degree from Bryant University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 27/02/2026 | 84.000 ( 0,02% ) | 559 440 $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| NUVATION BIO INC. | Corporate Officer/Principal | 28/03/2024 |
| Società | Posizione | Fine |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Vendite & Marketing | 01/12/2023 |
| MIRATI THERAPEUTICS | Vendite & Marketing | 01/09/2022 |
| KITE PHARMA INC | Vendite & Marketing | 01/04/2021 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer therapies | Health Technology |
Bryant University
Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kite Pharma, Inc.
Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale